This open-label, single-arm, Phase II multi-center study will enroll approximately 42
subjects and investigate the activity, pharmacokinetics and safety of ruxolitinib added to
the subject's immunosuppressive regimen among infants, children, and adolescents aged 28
days to <18 years old with either moderate to severe treatment-naive cGvHD or SR-cGvHD.
Subjects will be grouped according to their age as follows: Group 1 includes subjects 12y to
<18y, Group 2 includes subjects 6y to <12y, Group 3 includes subjects 2y to <6y, and Group
4 includes subjects 28days to <2y.
Graft-Versus-Host Disease (GVHD),
graft versus host disease,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.